Kendle International — Investor Presentation (August 2005)
29 slides from Kendle International's investor presentation, Aug 8, 2005
Slide 1: Kendle on the move August 2005
Kendle on the move August 2005
Slide 2: Safe Harbor
Safe Harbor Information herein contains forward-looking statements pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are based largely on management's expectations and are subject to risks and uncertainties that could c
Slide 3: Kendle Vision
Kendle Vision North America + Europe + Asia/Pacific + Latin America + Africa
Slide 4: Kendle Vision: On the path to shareholder value
Kendle Vision On the path to shareholder value; striving to outperform the CRO sector Platform for growth Clear imperatives and organizational realignment have accelerated recovery Percentage sales growth in 2004 tripled the reported industry average Future challenges Return to double-digit operatin
Slide 5: The Path to Shareholder Value
The Path to Shareholder Value Continued future growth Clinical Development Phase I - IV Accelerated organic growth Recovery Commercialization Pre-clinical Competency Broader acquisition strategy Adjacent acquisitions Share growth Phase I - IV Imperatives Organizational realignment Longer term Mid te
Slide 6: Market Benchmarks
Market Benchmarks North America + Europe + Asia/Pacific + Latin America + Africa
Slide 7: Strong Growth in Gross Sales
2003 Strong Growth in Gross Sales $Million Q1 Q2 Q3 Q4 70 70 58 53 53 47 55 33 73 80 2004 2005 +38% +38%
Slide 8: Strong Growth in Net Sales
Strong Growth in Net Sales $Million 63 62 53 51 38 36 53 21 66 70 2003 2004 2005 Q1 Q2 Q3 Q4 +29% +32%
Slide 9: Growth in Net Revenues vs Peer Group
Growth in Net Revenues Peer* Group Kendle 12.7% 16.9% Q1 2005 * Peer Group includes PPD, Parexel, PRA and ICON. Peer* Group Kendle 12.8% 21.2% Q2 2005 Peer* Group Kendle 10.6% 10.7% 2004
Slide 10: Operating Margin Comparison
Operating Margin Comparison Peer* Group Kendle 14.4% 6.0% Q1 2005 * Peer Group includes PPD, Parexel, PRA and ICON. Peer* Group Kendle 11.8% 7.3% Q2 2005 Peer* Group Kendle 13.4% 3.9% 2004
Slide 11: Growth Indicators
Growth Indicators North America + Europe + Asia/Pacific + Latin America + Africa
Slide 12: Growth in Number of RFPs Received
Growth in Number of RFPs Received +14% 2004 2003 Large $ value awards 2005 +28% - -14.4%
Slide 13: Improvement in Quality and Value of RFPs
Improvement in Quality and Value of RFPs Growth in quality and alignment of RFPs to Kendle core competencies Q1 '05 vs. Q1 '04 and Q2 '05 vs. Q2 '04 Total RFPs Service Brand RFPs Multiple Service RFPs
Slide 14: Growth in Customer MSAs Versus Prior Year
Growth in Customer MSAs Versus Prior Year 2003 2004 More strategic relationships leading to win/win efficiencies +26% +42%
Slide 15: Kendle: Performance Where it Counts
Kendle Performance Where it Counts North America + Europe + Asia/Pacific + Latin America ‘Africa
Slide 16: Project Leadership at Kendle
Kendle Project Leader Project Leadership at Kendle Enhanced Communication Proactive Solution Focus Direct Access to Senior Management Full Accountability Winner of Pharmaceutical Times Project Team of the Year, 2005
Slide 17: Staying Ahead of the Industry Trend
Staying Ahead of the Industry Trend Oncology CNS Leadership within therapeutic areas: Adjunctive therapy in Oncology Inflammation development experience best in class Suite of Respiratory studies Delivery of challenging studies e.g: pediatric GERD Therapeutic expertise Project portfolio aligned with
Slide 18: Strong Business Mix in Q2 2005
Strong Business Mix in Q2 2005 Top five customers represented 34% of revenue and 51% of gross sales Revenue distribution 56% North America, 40% Europe and 4% Asia-Pacific Biotech represented approximately one-third of new business awards Awards in Oncology and CNS therapy areas showing growth above
Slide 19: Key Issues and Solutions
Key Issues and Solutions
Slide 20: 1. Translating Strong Backlog Into Results
1. Translating Strong Backlog Into Results Operating Margin Leveraging SGA Preferred Customer Efficiencies Process Improvement 10% 14%
Slide 21: 2. Punching More Than Our Weight
2. Punching More Than Our Weight New geography offers new capacity - Romania, Bulgaria, Peru (2004) and India, South Africa (2005) Geographic expansion targets for review include LA, CEE as a priority and Asia-Pacific as secondary opportunity Acquisition opportunities to focus on adjacencies aligned
Slide 22: Financial Results: Three Months Ended June 30
NET SERVICE REVENUES* OPERATING INCOME* OPERATING MARGIN DILUTED EARNINGS PER SHARE NORTH AMERICAN REVENUE % Financial Results THREE MONTHS ENDED June 30 2005 2004 $41,217 $287 0.6% $0.02 59% $49,965 $3,652 7.3% $0.10** 56% *(000s) **Includes one-time, non-cash charge to reflect the write-off of def
Slide 23: Financial Results: Six Months Ended June 30
NET SERVICE REVENUES* OPERATING INCOME* OPERATING MARGIN DILUTED EARNINGS PER SHARE NORTH AMERICAN REVENUE % Financial Results SIX MONTHS ENDED June 30 2005 2004 $82,003 $983 1.2% $0.07 60% $97,652 $6,501 6.7% $0.26** 56% *(000s) **Includes one-time, non-cash charge to reflect the write-off of defer
Slide 24: Financial Highlights Q2 2005
Financial Highlights Q2 2005 OPERATING CASH FLOW CASH AND AVAILABLE-FOR-SALE SECURITIES WORKING CAPITAL TOTAL ASSETS CREDIT FACILITY DEBT SHAREHOLDERS' EQUITY $3.1 million $29.9 million $45.3 million $156.0 million $5.5 million $104.8 million
Slide 25: 2005 Guidance
2005 Guidance 2004 2005 est Growth Net Service Revenue* $172.9 $200 - $210 15.7% - 21.5% Pro forma EPS** $0.25 $0.79 - $0.84 216.0% - 236.0% * Millions ** Pro forma EPS excludes gain on debt extinguishment from both years, severance costs associated with workforce re-alignment in 2004 and write-off
Slide 26: Why Invest in Kendle?
Why Invest in Kendle? Significant improvement - Q2 2005 vs. Q2 2004 New business awards of $80 million, up 38 percent Total business authorizations of $273 million, up nearly 33 percent Net service revenues of $50 million, up 21 percent EPS of $0.10 per share, up 400 percent Continued strong cash fl
Slide 27: Stock performance
Kendle Stock performance KENOLE INTL INC a3 of 4-Aug-2005 20 5 600 c S Feneedinend FIRPA Dee lethal u 0 al Copyright. 2005 Yahoo! Inc. http://Finance yahoo .com/ North America + Europe + Asia/Pacific + Latin America® Africa aaa
Slide 28: Real results.
eal results.®
Slide 29: Key Performance Indicators
Key Performance Indicators 2004 Q1 2005 Q2 2005 New Revenue Growth Kendle 10.7% 16.9% 21.2% Peer Group 9.9% 13.5% 14.3% Operating Margin Comparison Kendle 3.9% 6.0% 7.3% Peer Group 13.5% 14.4% 12.1% Growth in Backlog Kendle 31.1% 32.0% 32.5% Peer Group 20.6% 18.8% 17.0% Net Book to Bill Kendle 1.32
Kendle International — Investor Presentation (August 2005) on 6ix